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ChickenpoxWhile trying to generate a site-directed deletion in the ORF63 latency-associated gene of varicella-zoster
virus (VZV) Oka, we constructed a virus with an unexpected rearrangement. The virus has a small deletion
in both copies of ORF63 and two copies of a cassette inserted between ORFs 64/65 and 68/69 containing
(a) truncated ORF62, (b) ORF63 with a small deletion, and (c) full-length ORF64. The virus was not
impaired for growth in human cells, induced higher levels of neutralizing antibodies in guinea pigs, and was
impaired for latency in cotton rats compared with parental virus (p=0.0022). Additional mutants con-
taining the same truncation in ORF62, with or without the ORF63 deletion, were less impaired for latency.
A VZV Oka mutant, replicating to similar titers and inducing a comparable immune response as parental
virus, but impaired for latency, might serve as a safer vaccine and be less likely to reactivate to cause
zoster.tious Diseases, Bldg. 10, Rm.
SC 1888, Bethesda, MD 20892-
g's College Circle, Room 6360,
to, Ontario, Canada M5S 1A8.
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Varicella-zoster virus (VZV) causes chickenpox and the virus may
reactivate later in life to cause shingles. A vaccine to prevent varicella
was developed by Takahashi et al. (1974) and approved for use in
the United States in 1995. A zoster vaccine was approved for use in the
United States in 2006 (Oxman et al., 2005). Both of these vaccine
viruses use the Oka strain of VZV, although the titer of virus in the
inoculum is about 14-fold higher in the zoster vaccine than in the
varicella vaccine.
The Oka varicella vaccine is usually well tolerated. The most
common side effects are injection site reactions, fever, and rash.
Breakthrough cases of chickenpox and herpes zoster were also
frequently reported as adverse reactions (Wise et al., 2000; Sharrar
et al., 2001). Rashes account for more than half of the adverse event
reports. Rashes due to wild-type virus were present at a median of
8 days after vaccination, while rashes associated with vaccine virus
occurred at a median of 3 weeks after vaccination (Sharrar et al.,
2001). Zoster occurring after vaccinationmay be due to reactivation of
wild-type or vaccine virus. In one study, wild-type virus was detected
in zoster lesions from 12 children at a median of 3 weeks aftervaccination, while vaccine virus was present in lesions from 14
children a median of 19 weeks after vaccination (Wise et al., 2000). In
another study, wild-type virus was conﬁrmed in zoster lesions from
10 patients at a median of 81 weeks after vaccination, while 22
patients had vaccine virus in zoster lesions a median of 28 weeks after
vaccination (Sharrar et al., 2001). Three patients in the latter study
had lesions at the site of the vaccine injection. While zoster due to
vaccine virus is uncommon, it is more prevalent in immunocompro-
mised persons who receive the varicella vaccine. Thus, a varicella
vaccine that is less likely to establish latency would likely be safer in
that there should a lower risk of zoster, especially in immunocom-
promised persons.
VZV establishes latency in cranial nerve and dorsal root ganglia.
Six VZV genes, ORF4, ORF21, ORF29, ORF62, ORF63, and ORF66
are expressed during latency in humans (Cohrs et al., 2003; Kennedy
et al., 2000; Meier et al., 1993). ORF63 transcripts are the most
abundant viral mRNAs expressed in latently infected human ganglia
(Cohrs and Gilden, 2007; Cohrs et al., 2000). Therefore, we have
constructed mutants in the ORF63 gene in an attempt to construct
viruses with different latency phenotypes.
Here we describe a VZV mutant that we constructed in the
Oka vaccine virus which replicates to titers similar to parental
virus in human cells and which is impaired for latency in a rodent
model. The vaccine induces higher levels of neutralizing antibody
to VZV than the parental virus in guinea pigs. Thus, the VZV
Oka mutant we describe here might be safer than the current Oka
vaccine in that it might be less likely to reactivate and cause
zoster.
Fig. 2. Southern blots of VZV ROka, ROka-NLS, ROka63-AatII-62t, and ROka-62t. Virion
DNAs were cut with NotI (A) or BamHI (B), separated on agarose gels, transferred to
nylon membranes, and hybridized with probes to ORF63 (A) or to ORF62 (near the 5′
end, corresponding to amino acids 140-360).
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Construction and growth properties of VZV ROka-NLS
In an attempt to produce VZV deleted for both copies of the
carboxy-terminal nuclear localization of ORF63, melanoma cells were
cotransfected with (a) the VZV insert from plasmid p63-30-4 which
has a small deletion in ORF63, at the site of the carboxy-terminal
nuclear localization signal, ﬂanked by a portion of ORF62 and full-
length ORF64 and (b) VZV virion DNA puriﬁed from ROka63D (which
is deleted for over 95% of both copies the ORF63 gene) (Fig. 1).
Homologous recombination between the plasmid and the virion DNA
should result in replacementof both copies of the largedeletion inORF63
with ORF63 having a smaller deletion. After transfection, cells with
cytopathic effects typical for VZVwere observed and viruswas passaged
in melanoma cells, plaque puriﬁed 4 times so that virus only with the
small deletion inORF63 could be detected by PCR. Aﬁfth roundof plaque
puriﬁcation was then done and Southern blotting was performed.
Sequence analysis of DNA ampliﬁed by PCR from ROka-NLS
indicated that both copies of ORF63 had the small deletion in the
carboxyl terminal nuclear localization sequence, and that two copies
of a cassette containing VZV nucleotides 106,614 to 112,214 were
inserted between ORF64/65 and ORF68/69. This cassette contains
(a) a portion of the amino-terminus of ORF62 (amino acids 1–839),
(b) ORF63 with a deletion in the carboxy terminal nuclear localiza-
tion sequence (NLS), and (c) full-length ORF64 followed by 110
nucleotides in the region between ORF64 and ORF65 (ROka-NLS,
Fig. 1). The 3′ end of the cassette (which ends after ORF64) had been
inserted into the VZV genome by homologous recombination, while
the 5′ end of the cassette (within ORF62) had been inserted by non-
homologous recombination.
Digestion of virion DNA from cells infected with VZV ROka or with
ROka-NLS with NotI, followed by hybridization with a probe to ORF63
showed a band of 11.8 kb in cells infected with ROka and bands ofFig. 1. Structures of VZV ROka, ROka-NLS, ROka63-AatII-62t, and ROka-62t. Compared with
insertion of a cassette containing a truncated form of ORF62, a deleted version of ORF63, and
of ORF62 present in ROka-NLS inserted between ORF65 and ORF66. ROka63-AatII-62t has the
the deletion in both copies of ORF63 that are present in ROka-NLS. ROka-NLS and ROka63-Aa
ROka63D has a large deletion in ORF63 (63D) and ORF70 (70D).11.8 kb and 5.6 kb in cells infectedwith ROka-NLS due to the two inserts
each containing an additional copy of ORF63 in ROka-NLS (Fig. 2A).
ROka-NLS grew to peak titers similar to those of ROka in
melanoma cells (Fig. 3). As expected, plaque sizes in cells infected
with ROka-NLS were similar to those of cells infected with ROka (data
not shown). Plaques in guinea pig embryo ﬁbroblasts are irregular;VZV ROka, ROka-NLS has deletions in both copies of ORF63 (ORF63 and ORF70) and
full-length ORF64 between ORF 64/65 and ORF68/69. ROka-62t has the truncated form
truncated form of ORF62 present in ROka-NLS inserted between ORF65 and ORF66 and
tII-62t have a small deletion in ORF63 (63d) and its duplicated gene ORF70 (70d), while
Fig. 3. Growth of VZV ROka, ROka-NLS, ROka63-AatII-62t, and ROka-62t in cell culture.
Melanoma cells were infected with each virus and at days 1 to 5 after infection the cells
were treated with trypsin and the titer of cell-associated virus was determined on
melanoma cells. Each data point shown is the average of two separate values.
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to VZV glycoprotein E. Infected foci in guinea pig embryo ﬁbroblasts
infected with ROka (mean surface area=630,000 units) were slightly
larger than those infected with ROka-NLS (mean surface area 460,000
units; p=0.02).
VZV ROka-NLS expresses a truncated ORF62 transcript, but a truncated
IE62 protein is not detected
Since ROka-NLS contains both full-length and truncated copies of
ORF62, Northern blotting was performed to determine if both forms
of ORF62 transcripts were expressed. A transcript of 4.2 kb was
detected in cells infected with VZV ROka, corresponding to full-
length ORF62 RNA, while transcripts of 4.2 and 2.2 kb were detected
in cells infected with ROka-NLS (Fig. 4A). The ratio of the amount ofFig. 4. VZV ROka-NLS, ROka63-AatII-62t, and ROka-62t each express a truncated ORF62 tran
each virus, separated on an agarose gel, transferred to a nylon membrane, and hybridized
representative result is shown. (B) The ratio of the intensity of the ORF62 full-length transc
viruses. The results shown were derived from four separate experiments and the vertical li4.2 kb (full-length ORF62) RNA to 2.2 kb (truncated ORF62) RNA was
1.0 in ROka-NLS (Fig. 4B). The presence of equimolar amounts of the
two transcripts supports the fact that there are two copies of full-
length and two copies of truncated ORF62 genes in ROka-NLS.
To determine if the truncated ORF62 transcript is expressed in
virus-infected cells, immunoprecipitations of radiolabeled lysates
from cells infected with VZV ROka or ROka-NLS were performed.
Bands of about 175 kDawere detected using antibody to 1–735 of IE62
(Fig. 5A) or full-length IE62 (Fig. 5B). The smaller bands may repre-
sent degradation products of IE62. Since a truncated form of IE62
might have a conformation that is not detectable by immunopre-
cipitation, immunoblotting was performed using lysates from cells
infected with VZV ROka and ROka-NLS. A band of approximately
175 kDa was detected in cells infected with ROka and ROka-NLS using
antibody directed against amino acids 1–735 of IE62 (Fig. 5C) or full-
length IE62 (Fig. 5D). Taken together, these data indicate that while
ROka-NLS expresses full-length IE62 protein and a truncated ORF62
transcript, the truncated IE62 protein is not expressed at detectable
levels. Levels of VZV IE63, thymidine kinase, ORF40 major nucleocap-
sid protein, and gE were similar in cells infected with VZV ROka and
ROka-NLS (data not shown).
VZV ROka-NLS is impaired for latency in cotton rats
To determine if ROka-NLS is important for VZV latency, cotton
rats were inoculated intramuscularly with ROka-NLS or parental
ROka virus. Five to 6 weeks later, animals were sacriﬁced and dorsal
root ganglia were examined for viral DNA. In the ﬁrst experiment,
80% of animals receiving VZV ROka and 30% receiving ROka-NLS had
a latent VZV infection and the geometric mean copy numbers were
263 VZV genomes for animals infected with VZV ROka and 23 for
those infected with ROka-NLS (Fig. 6A). In the second experiment,
60% of animals infected with VZV ROka and 25% infected with ROka-
NLS developed a latent VZV infection and the geometric mean copy
numbers were 39 viral genomes for animals infected with VZV ROka
and 22 for animals infected with ROka-NLS (Fig. 6B). The combined
results of 5 separate experiments indicated that 35 of 50 (70%) of
animals inoculated with ROka had latent VZV DNA, while 18 of 48
(38%) of animals infected with ROka-NLS had latent VZV (p=0.0022,
Fisher's exact test) (Table 1).script at similar levels. (A) Total RNA was isolated from melanoma cells infected with
with a radiolabeled probe to ORF62. The experiment was performed four times and a
ript (4.2 kb band) to the ORF62 truncated transcript (2.2 kb band) is plotted for each of
nes show standard deviations.
Fig. 5. Expression of IE62 is similar in cells infected with VZV ROka, ROka-NLS, ROka63-AatII-62t, and ROka-62t by immunoprecipitation or immunoblotting. Immunoprecipitation of
cell lysates infected with the viruses probed with antibody to 735 amino acids of IE62 (A) or to full-length IE62 (B). Immunoblot of cells infected with the viruses probed with
antibody to 782 amino acids of IE62 (C) or to full-length IE62 (D).
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ROka in guinea pigs
To measure VZV neutralizing antibody to VZV ROka-NLS, guinea
pigs were inoculated with cell culture medium, uninfected cells,
ROka-infected cells, or ROka-NLS-infected cells and after the third
inoculation serum was obtained. Animals immunized with ROka-NLS
had signiﬁcantly higher neutralizing titers than those immunized
with ROka (p=0.002, Table 2). Animals vaccinated with ROka or
ROka-NLS had higher neutralizing antibody titers than animals re-
ceiving uninfected cells or medium alone (pb0.0001).
VZV with a truncation of ORF62 and the deletion in ORF63 is less
impaired for latency than ROka-NLS
ROka-NLS has several differences from ROka that might be
responsible for the reduced latency observed in rodents. Two of theFig. 6. Estimated copy number of VZV genomes in latently infected cotton rats from
experiments 1 (A) and 2 (B) in Table 1. The geometric mean number of VZV genome copy
numbers per 500 ng of ganglia DNA in PCR-positive ganglia is shown at the bottom of the
ﬁgure. Filled circles below the horizontal line represent samples whose copy numbers
were below the limit of detection (b10 copies per 500 ng of DNA), and ﬁlled circles above
the line show the viral copy number for samples above the limit of detection.changes affect proteins that are expressed during latency. ROka-NLS
has two copies of a truncated form of IE62 and a deletion in the
carboxy-terminal nuclear localization signal in each copy of ORF63. To
determine which features of ROka-NLS are responsible for its
impairment in latency, we inserted the truncated form of IE62
found in ROka-NLS into VZV ROka to generate ROka-62t (Fig. 1). We
also inserted the truncated form of IE62 into ROka63-AatII30-4 which
has the deletion in the carboxy terminal nuclear localization signal of
ORF63 which is present in ROka-NLS to generate ROka63-AatII-62t
(Fig. 1).
VZV ROka-62t and ROka63-AatII-62t had the expected genome
conﬁguration. BamHI restriction endonuclease digestion of virion
DNA from ROka or ROka-NLS followed by hybridization with a probe
to the 5′ end of ORF62 showed a band of 4.7 kb, while digestion of
virion DNA from ROka-62t and ROka63-AatII-62t showed bands of 4.7
and 3.8 kb due to insertion of IE62t into the Avr II site located between
ORF65 and ORF66 (Fig. 2B).
VZV ROka-62t and ROka63-AatII-62t grew to similar titers as
parental virus and ROka-NLS (Fig. 3). ROka-62t and ROka63-AatII-62t
expressed a truncated ORF62 transcript at similar levels to that seen in
ROka-NLS (Fig. 4). Expression of IE62 was the same in cells infected
with ROka-62t, ROka63-AatII-62t, and ROka-NLS (Fig. 5).
To determine if ROka-62t and ROka63-AatII-62t are impaired for
latency similar to ROka-NLS, cotton rats were inoculated with the
viruses and dorsal root ganglia were analyzed for VZV DNA 5 to 6
weeks later. Sixteen of 30 (53%) animals inoculated with ROka-62tTable 1
VZV ROka-NLS is impaired for latency.
Expt. No. of latently infected animals/Total no. of animals infected
ROka ROka-NLS ROka63-AatII-62t ROka-62t
1 8/10 3/10 ND ND
2 6/10 2/8 ND ND
3 9/10 6/10 6/10 6/10
4 6/10 2/10 4/10 5/10
5 6/10 5/10 3/10 5/10
Total 35/50 (70%) 18/48 (38%) 13/30 (43%) 16/30 (53%)
Table 2
VZV neutralization titers in animals immunized with VZV ROka and ROka-NLSa.
Inoculum 50% VZV-neutralization titer
after vaccination (95% CIb)
Medium 1.4 (1.0, 4.7)
Uninfected cells 3.5 (1.8, 5.6)
ROka 23 (20, 26)
ROka-NLS 30 (27, 34)
a Data based on 3 animals receiving medium alone, and 5 animals each receiving
uninfected cells, ROka-infected cells, or ROka-NLS infected cells.
b CI, conﬁdence intervals.
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VZV DNA in their dorsal root ganglia, compared with 70% of animals
infected with ROka or 38% of animals with ROka-NLS. The difference
between ROka and ROka-62t was not signiﬁcant (p=0.155, Fisher's
exact test), while the difference between ROka and ROka63-AatII-62t
was signiﬁcant (p=0.033, Fisher's exact test). These data indicate
that the combination of the ORF62 truncation and the ORF63 deletion
contribute to the latency phenotype observed in ROka-NLS.
Discussion
We have shown that a VZV Oka mutant virus is impaired for
latency in rodents, grows to peak titers similar to those seen with
parental virus in vitro, and induces higher titers of neutralizing
antibodies than parental virus in guinea pigs. The VZV Oka mutant
grew in cell culture to similar titers as the Oka vaccine strain from
which it was derived. Since the original Oka vaccine strain is
attenuated in humans, we suspect that the VZV Oka mutant would
also be attenuated in humans.
Vaccine virus has been isolated from zoster lesions in both children
and adults vaccinated with the varicella vaccine (Liang et al., 1998;
Hammerschlag et al., 1989; Plotkin et al., 1989; Quinlivan et al., 2007).
The VZV Oka vaccine is less likely to reactivate to cause zoster than
wild-type virus in children with leukemia (Brunell et al., 1986;
Kamiya et al., 1984). Hardy et al. (1991) found that the rate of zoster
among vaccinated children with leukemia was three-fold lower than
the rate of zoster in children previously infected with wild-type virus.
Eighty-ﬁve percent of the vaccinated children with zoster had a rash
associated with the vaccination or from breakthrough varicella after a
household exposure before their episode of zoster. Broyer et al.
(1997) reported rates of zoster in renal transplant recipients of 7% in
children who had received the varicella vaccine, compared with 13%
who had a history of natural varicella. While it is assumed that the
vaccine virus is also less likely to reactivate to cause zoster than
wild-type virus in immunocompetent children, this has not yet been
demonstrated.
It is possible that subclinical reactivation of the vaccine virusmight
occur and be a valuable feature of the vaccine in that it would result in
boosting of the immune response to the virus over time. Krause and
Klinman (2000) found that titers of antibody to VZV rose over time in
vaccinees with low VZV titers at higher rates than would be expected
from exposure towild-type varicella, suggesting that the vaccine virus
was undergoing subclinical reactivation with boosting of the immune
response. However, this hypothesis is controversial and other inves-
tigators feel that the rise in antibody titers years after vaccination is
more likely due to exposure to wild-type virus than reactivation of
vaccine virus (Seward et al., 2000; LaRussa et al., 2000). In addition,
the recent approval of a second dose of varicella vaccine for children at
age 4–6 years after the ﬁrst dose at 12–15months (Centers for Disease
Control, 2007) suggests that a single dose does not provide full pro-
tection which might occur if the vaccine virus was able to undergo
subclinical reactivation and boosting.
The frequency of zoster occurring after varicella vaccination of
healthy adults is unknown. In a passive, voluntary postmarketingstudy of varicella vaccinees after licensure in the United States, 205
cases of zoster occurred more than 6 weeks after vaccination. Of the
32 cases in which the origin of the virus was determined by PCR, 22/
32 (69%) of cases were due to vaccine virus and 10/32 (31%)were due
to wild-type virus (Sharrar et al., 2001). Thus while the Oka vaccine
can reactivate to cause zoster, the true incidence of this phenomenon,
especially in adults, is not known.
We found that ROka63-AatII-62t was partially impaired for
latency, but to a lesser extent than ROka-NLS. ROka63-AatII-62t has
both the truncated version of ORF62 and the deletion in both copies of
ORF63 that are found in ROka-NLS. Insertion of the truncated version
of ORF62 into ROka had a minimal effect on latency (ROka-62t, Table
1), and a prior study showed that virus with only the carboxy terminal
nuclear localization signal deletion in both copies of ORF63 (ROka63-
AatII30-4) was not signiﬁcantly impaired for latency (Cohen et al.,
2005a). Thus, both the ORF62 truncation and ORF63 deletion
contribute to the latency phenotype observed in ROka-NLS. While
the ORF62 protein has been shown to interact with the ORF63 protein
(Lynch et al., 2002), the interaction domain in the ORF63 protein is at
amino acids 55 to 67 (Baiker et al., 2004) of the ORF62 protein, not in
the area deleted in ROka-NLS.
The contribution of the ORF62 truncation to the latency phenotype
in ROka-NLS is intriguing in view of experiments comparing viral
transcription in cells infected with parental and vaccine strain Oka
viruses. Transcription of ORF62 is reduced in cells infected with Oka
vaccine virus, compared with parental Oka virus (Cohrs et al, 2006;
Grinfeld et al. 2009). While we did not detect a difference in ORF62
transcription in cells infected with ROka-NLS in vitro, it is possible
that differences might occur during lytic or latent infection in vivo.
Transcripts were detected from the truncated copy of ORF62;
however, truncated protein could not be detected. While truncated
forms of ORF62 can be expressed by transient transfection using a
different viral promoter (Baudoux et al., 1995), it is possible that (a)
the truncated protein is not made or is less stable in the context of
virus infection, or (b) that the expression level of truncatedmutants is
lower when expressed from its native promoter.
Analysis of several other VZV mutants showed that most are
dispensable for latency in rodents. VZV unable to express ORFs 1, 2,
10, 13, 14, 17, 32, 47, 57, 61, 66, or 67 was dispensable for latency in
rodents (Grinfeld et al., 2004; Sato et al., 2002a,b; Sato et al., 2003a,b).
While deletion of ORFs 4, 29, or 63 resulted in viruses which were
impaired for latency in cotton rats (Cohen et al., 2005a,b; Cohen et al.,
2007), each of these mutants was either replication defective or
markedly impaired for growth in cell culture. Only one other VZV
mutant, which expresses ORF29 protein from a CMV promoter is also
impaired for latency in rodents and replicates to titers similar to
parental virus (Cohen et al., 2007). Thus ROka-NLS is only the second
VZV mutant that is impaired for latency in an animal model, but not
for replication in cell culture.
Materials and methods
Cells, viruses, plasmids, and transfections
Humanmelanoma (MeWo) cells were a gift fromCharles Grose (U.
Iowa) and were used for transfections and propagation of virus.
Guinea pig embryo ﬁbroblasts were obtained from BioWhittaker
(Walkersville, MD). VZV recombinant Oka virus (ROka) and recom-
binant Oka virus deleted for both copies of ORF63 (ROka63D) have
been described previously (Cohen et al., 2004).
Cosmids VZV NotIA, NotIB, MstIIA, and MstIIB are derived from the
Oka strain of VZV and encompass the entire genome. Cosmid MstIIA-
63AatII30-4 has a deletion in the carboxy-terminal nuclear localiza-
tion signal of both copies of ORF63 (Cohen et al., 2005a).
Plasmid p63-30-4 contains a portion of ORF62, a deletion (VZV
nucleotides 111,335 to 111,379) in ORF63 which removes the
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described previously (Cohen et al., 2005a) (Fig. 1).
A plasmid containing a truncated version of ORF62 was con-
structed by PCR amplication of ROka-NLS using primers 5′-GCATACC-
TAGGTTACGTGAACACCACAAC (containing an Avr II site [underlined]
and VZV nucleotides 109,761–109,742) and 5′ GCATACCTAGGCCG-
CGCCGAATTATATGACC (containing an Avr II site [underlined] and
VZV nucleotides 112,002–112,021), cutting the PCR product with Avr
II and cloning the DNA into the Avr II site of LITMUS 28i (New England
Biolabs, Beverly, MA) to create plasmid 62t.
Cosmid MstIIA-62t was constructed by cutting cosmid MstIIA with
Avr II and inserting the Avr II fragment with the truncated portion of
ORF62 from ROka-NLS obtained from plasmid 62t. The resulting
cosmid MstIIA-62t has two full-length copies of ORF62 and one
truncated copy of ORF62.
Cosmid MstIIA-63AatII30-4-62t was constructed by cutting cos-
mid MstIIA-63AatII30-4 with Avr II and inserting the Avr II fragment
with the truncated portion of ORF62 from plasmid 62t as described
above. The resulting cosmid has two full-length copies of ORF62, one
truncated copy of ORF62, and a deletion in the carboxy-terminal
nuclear localization signal of both copies of ORF63.
Recombinant viruses with the truncated copy of ORF62weremade
by transfecting melanoma cells with the MstIIA cosmids with the
ORF62 truncation along with cosmids MstIIB, NotIA, and NotIB and
plasmid pCMV62 by the calcium phosphate transfection procedure
(Cohen et al., 2005a).
Southern blotting, Northern blotting, immunoblotting, and
immunoprecipitations
Southern blotting was performed using virion DNA isolated from
VZV mutants, digesting the DNA with restriction enzymes, fraction-
ating the DNA on agarose gels, and transferring the DNA to nylon
membranes. The membranes were probed with [32P]dCTP radiola-
beled probes corresponding to ORF62 nucleotides 421–1081 or full-
length ORF63.
For Northern blotting, RNA was isolated from VZV-infected cells
using TRIzol reagent (Invitrogen, Carlsberg, CA), separated on a
formaldehyde gel, transferred to nitrocellulose, and hybridized to a
[32P]dCTP radiolabeled probe corresponding to VZV nucleotides
421–1081 of ORF62. Radioactivity in DNA bands on the gel was quan-
tiﬁed using a PhosphorImager and ImageQuant software (Molecular
Dynamics, Piscataway, NJ).
Immunoblots were performed using lysates of VZV-infected
melanoma cells prepared in RIPA buffer (0.01 M Tris pH 7.4, 0.15 M
NaCl, 1% NP-40, 1% DOC, 0.1% SDS). After fractionation on SDS-
polyacrylamide gels and transfer to nylon membranes, the blots were
incubated with rabbit polyclonal antibodies to IE62. One antibody,
#18 (a gift fromWilliam T. Ruyechan) was targeted to amino acids 1–
735 of IE62 (Spengler et al., 2000), while the other antibody (a gift
from Paul R. Kinchington) was made by immunizing rabbits with a
mixture of puriﬁed proteins (amino acids 1 to 161, 162 to 506, 506 to
1310, and 417 to 824 representing full-length VZV IE62 [Kinchington
et al., 2000]).
For immunoprecipitations, cells were radiolabeled with [35S]
methionine and lysed in RIPA buffer. Antibody to IE62 was added
to the lysates followed by protein G, the immune complexes were
separated on SDS-polyacrylamide gels, and autoradiography was
performed.
Virus growth studies
Flasks of melanoma cells were infected with VZV mutants at
37 °C and 1 to 5 days later the cells were treated with trypsin, and
serial dilutions of cells were used to infect melanoma cells in
6-well plates. One week later, the plates were stained with crystalviolet and the number of plaques was counted. Immunoﬂuorescent
foci of VZV-infected guinea pig cells in 6-well plates were measured
by ﬁxing virus-infected cells with methanol-acetone (1:1 [vol/vol]),
incubating with mouse monoclonal antibody to VZV glycoprotein
E (Chemicon, Temecula, CA) followed by Alexa 488-conjugated
anti-mouse antibody (Molecular Probes, Eugene, OR), and mea-
suring the size of immunoﬂuorescent foci using Image J software
(http://rsb.info.nih.gov/ij/).
Analysis of immune responses
Four- to 6-week-old female Hartley guinea pigs were vaccinated
subcutaneously with cell culture medium or human diploid ﬁbro-
blasts (MRC-5 cells) that were uninfected or infected with 1×105 PFU
of VZV ROka or ROka-NLS. Animals received three doses of vaccine at
monthly intervals. Serum was obtained 5 weeks after the third
vaccination. To determine the neutralizing titer, serum was diluted
1:4, 1:8, 1:16, 1:32, 1:64, and 1:128 in SPGC (10% fetal bovine serum,
0.1% sodium glutamate, 5% sucrose in PBS) and each dilution (0.3 ml)
was mixed with 100 PFU of VZV Oka vaccine strain (0.3 ml). The
mixture was incubated for 1 h on ice and 0.5 ml of the mixture was
added to each well of a 6-well plate of melanoma cells. After incuba-
tion for 1 h at 37 °C, 3.5 ml of additional medium was added. After 10
days, the cells were ﬁxed and stained with crystal violet. VZV
neutralizing antibody titers were deﬁned as the concentration of
guinea pig serum required to reduce the number of plaques by 50%
compared to PBS.
Analysis of latent infection
Four- to 6-week-old female cotton rats were inoculated intra-
muscularly along the spine with VZV-infected melanoma cells
containing 1.75×105 PFU of VZV. Five to 6 weeks later, animals
were sacriﬁced and DNA was isolated from pooled dorsal root
ganglia. PCR was performed using 500 ng of dorsal root ganglia DNA
or serial dilutions of VZV cosmid NotIA in 500 ng of DNA from
uninfected cotton rats and primers corresponding to ORF 21 (Cohen
et al., 2004). PCR products were analyzed on a Southern blot using a
radiolabeled probe to ORF21. The lower limit of detection of DNA
was 10 copies of viral DNA when the viral DNA was mixed with
500 ng of salmon sperm DNA. Copy numbers were estimated by
densitometry using a phosphorimager.
Statistics
To determine the 50% neutralization titers from the dilutions
tested, we assumed that the number of plaques follows a Poisson
distribution with a mean value depending on the dilution proportion.
An exponential mean function is used, where the mean titer of
neutralizing antibody is an exponential function of an intercept
and the log dilution proportion. We assume that the Poisson mean
is given by e(a+b log(X)) where X is the dilution number. We estimate
the unknown terms a and b, using the method of maximum
likelihood, which provides a smooth monotone estimate of the true
mean number of plaques for any dilution X. We then use this
smoothed estimate to determine the 50% neutralization dilution by
comparison of serum from infected to uninfected guinea pigs. The
average number of plaques in serum from uninfected guinea pigs was
90, based on two replicates. Thus the estimated titer that neutralizes
50% of virus plaques, say X50 solves e{a+ b log(X50)}/90=0.50.
Multiplying both sides by 90 yields e{a+b log(X50)}=45. Taking the
log of both sides yields a+b log (X50)=log(45). After subtracting a
and dividing by b, the equation becomes log(50)={log(45)−a}/b.
Then taking the anti-log of both sides we get 50=e[{log(45)−a}/b]. A
95% conﬁdence interval for the 50% neutralization dilution is
constructed by the likelihood ratio method. Comparisons between
200 A.P.N. Ambagala et al. / Virology 399 (2010) 194–200estimated 50% neutralizations under different conditions were
conducted by the likelihood ratio test statistic.
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